Related Experiment Video
Updated: Jun 5, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC"
1Department of Clinical Laboratory, People's Hospital of Qianxinan Prefectural, Guizhou Province, People's Republic of China.
No abstract available in PubMed .
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Related Concept Videos
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle